How to Cite
Abstract
Introduction: Diabetes mellitus is a risk factor for the development of coronavirus infection, which causes severe acute respiratory syndrome 2 (SARS-CoV-2). Aim: To analyze laboratory parameters that can be considered as risk factors for an unfavorable progression of the infection and, thus, to achieve an appropriate disease management
and obtain favorable results in its progression. Materials and methods: A total of 131 diabetic patients with COVID-19 diagnosis who had been admitted to hospital were included. Patients were divided into groups according to other comorbidities and infection severity. At admission, laboratory data of the following parameters were collected: white
blood cell, neutrophil and lymphocyte counts; glycemia, ferritin; D-dimer; C-reactive protein, procalcitonin, partial
pressure of oxygen and glycated hemoglobin. For the analysis, a Student’s t-test and a variance test were performed. An analysis of the main components was performed to evaluate the severity of the infection and comorbidities with the different variables. Results: Patients with severe disease presented significantly higher ferritin, C-reactive protein and procalcitonin concentrations than those with moderate disease (p < 0.05; p < 0.05; p < 0.01; respectively), but not for the rest of the parameters. A higher lymphocyte count was associated with the development of moderate disease. Conclusions: Diabetic patients with lower lymphocyte counts and higher ferritin and C-reactive protein concentrations have a higher risk of developing severe disease, regardless of the glycemia control.
References
Revised U.s. surveillance case definition for severe acute respiratory syndrome (SARS) and update on SARS cases United States and worldwide, December 2003. Cdc.gov. 2003 [citado el 16 de marzo de 2021]. Disponible en: https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5249a2.htm
Middle East respiratory syndrome coronavirus (MERS-CoV) [Internet]. Who.int. [citado el 16 de marzo de 2021]. Disponible en: https://www.who.int/health-topics/middle-east-respiratory-syndrome-coronavirus-mers
Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel Coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020; 382(8):727–33.
Alocución de apertura del Director General de la OMS en la rueda de prensa sobre la COVID-19 celebrada el 11 de marzo de 2020 (citado el 16 de Marzo del 2021). Who.int. Disponible en: https://www.who.int/es/directorgeneral/speeches/detail/who-director-general-s-opening-remarks-at-themedia-briefing-on-covid-19---11-march-2020
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395(10223):497–506.
Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA. 2020; 323(18):1775–6.
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395(10229):1054–62.
Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with Coronavirus disease 2019 pneumonia in Wuhan, China. JAMA InternMed. 2020; 180(7):934–43.
Guan W-J, Ni Z-Y, Hu Y, Liang W-H, Ou C-Q, He J-X, et al. Clinical characteristics of Coronavirus disease 2019 in China. N Engl J Med. 2020; 382(18):1708– 20. Disponible en: http://dx.doi.org/10.1056/NEJMoa2002032
Andersen CJ, Murphy KE, Fernandez ML. Impact of obesity and metabolic syndrome on immunity. AdvNutr. 2016; 7(1):66–75.
Francisco V, Pino J, Campos-Cabaleiro V, Ruiz-Fernández C, Mera A, Gonzalez-Gay MA, et al. Obesity, fat mass and immune system: Role for Leptin. Front Physiol. 2018; 9:640.
Andrade-Oliveira V, Câmara NOS, Moraes-Vieira PM. Adipokines as drug targets in diabetes and underlying disturbances. J Diabetes Res. 2015; 2015: 681612.
Bremer AA, Jialal I. Adipose tissue dysfunction in nascent metabolic syndrome. J Obes. 2013; 2013: 393192.
Faber DR, de Groot PG, Visseren FLJ. Role of adipose tissue in haemostasis, coagulation and fibrinolysis. Obes Rev. 2009; 10(5):554–63.
Bioquímico S-C, Bioquímicos De Importancia P. Org.ar. Disponible en: https://cofybcf.org.ar/src/img_up/25062020.1.pdf
Luzi L, Radaelli MG. Influenza and obesity: its odd relationship and the lessons for COVID-19 pandemic. ActaDiabetol. 2020;57(6):759–64.
MagdyBeshbishy A, Hetta HF, Hussein DE, Saati AA, C Uba C, Rivero-Perez N, et al. Factors associated with increased morbidity and mortality of obese and overweight COVID-19 patients. Biology (Basel). 2020; 9(9).
Benfield T, Jensen JS, Nordestgaard BG. Influence of diabetes and hyperglycaemia on infectious disease hospitalisation and outcome. Diabetologia. 2007; 50(3):549–54.
Suaya JA, Eisenberg DF, Fang C, Miller LG. Skin and soft tissue infections and associated complications among commercially insured patients aged 0-64 years with and without diabetes in the U.S. PLoS One. 2013;
(4):e60057.
The Emerging Risk Factors Collaboration. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011; 364(9):829–41.
Alahmad B, Al-Shammari AA, Bennakhi A, Al-Mulla F, Ali H. Fasting blood glucose and COVID-19 severity: Nonlinearity matters. Diabetes Care. 2020; 43(12):3113–6.
de Lucena TMC, da Silva Santos AF, de Lima BR, de Albuquerque Borborema ME, de Azevêdo Silva J. Mechanism of inflammatory response in associatedcomorbidities in COVID-19. Diabetes MetabSyndr. 2020; 14(4):597– 600.
Holman N, Knighton P, Kar P, O’Keefe J, Curley M, Weaver A, et al. Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study. Lancet Diabetes Endocrinol. 2020; 8(10):823–33.
Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by the novel Coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS Coronavirus. J Virol. 2020; 94(7).
Li XC, Zhang J, Zhuo JL. The vasoprotective axes of the renin-angiotensin system: Physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases. Pharmacol Res. 2017; 125(Pt A):21–38.
Who.int. [citado el 16 de marzo de 2021]. Disponible en: https://apps.who.int/iris/bitstream/handle/10665/330861/9789240001237-spa.pdf
Emergencies Preparedness. Antigen-detection in the diagnosis of SARSCoV-2 infection. Who.int. World Health Organization; 2021. Disponible en: https://www.who.int/publications/i/item/antigen-detection-in-the-diagnosis-of-sars-cov-2infection-using-rapid-immunoassays.
WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection. A minimal common outcome measure set for COVID-19 clinical research. LancetInfectDis. 2020 [citado el 16 de marzo de 2021]; 20(8):e192–7.
Chan JWM, Ng CK, Chan YH, Mok TYW, Lee S, Chu SYY, et al. Short term outcome and risk factors for adverse clinical outcomes in adults with severe acute respiratory syndrome (SARS). Thorax. 2003; 58(8):686–9.
Morra ME, Van Thanh L, Kamel MG, Ghazy AA, Altibi AMA, Dat LM, et al. Clinical outcomes of current medical approaches for Middle East respiratory syndrome: A systematic review and meta-analysis. RevMed Virol [Internet]. 2018; 28(3):e1977.
Iaccarino G, Grassi G, Borghi C, Ferri C, Salvetti M, Volpe M, et al. Age and multimorbidity predict death among COVID-19 patients: Results of the SARS-RAS study of the Italian society of hypertension: Results of the SARSRAS study of the Italian society of hypertension. Hypertension. 2020; 76(2): 366–72.
de Almeida-Pititto B, Dualib PM, Zajdenverg L, Dantas JR, de Souza FD, Rodacki M, et al. Severity and mortality of COVID 19 in patients with diabetes, hypertension and cardiovascular disease: a meta-analysis. DiabetolMetabSyndr. 2020; 12(1):75.
Rastogi A, Dogra H, Jude EB. COVID-19 and peripheral arterial complications in people with diabetes and hypertension: A systematic review. Diabetes MetabSyndr. 2021; 15(5):102204.
Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factorsassociatedwith COVID-19-related deathusingOpenSAFELY. Nature. 2020
American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 2005; 28 Suppl 1:S4–36.
Wang Z, Du Z, Zhu F. Glycosylated hemoglobin is associated with systemic inflammation, hypercoagulability, and prognosis of COVID-19 patients. Diabetes Res ClinPract. 2020; 164 (108214):108214.
Rosário C, Zandman-Goddard G, Meyron-Holtz EG, D’Cruz DP, Shoenfeld Y. The Hyperferritinemic Syndrome: macrophage activation syndrome, Still’s disease, septic shock and catastrophic antiphospholipidsidrome. BMC Medicine. 2013; 11:185.
Guo W, Li M, Dong Y, Zhou H, Zhang Z, Tian C, et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab Res Rev. 2020; e3319.